+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030- Product Image
Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030- Product Image
Sale

Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014438
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dengue Vaccine Market grew from USD 1.38 billion in 2023 to USD 1.53 billion in 2024. It is expected to continue growing at a CAGR of 11.79%, reaching USD 3.02 billion by 2030.

The scope and definition of the Dengue Vaccine market encompass a medical solution aimed at preventing dengue fever caused by the dengue virus, transmitted by Aedes mosquitoes. The necessity for the dengue vaccine is driven by the rising prevalence and outbreaks of dengue fever globally, with significant impacts in tropical and subtropical regions, intensifying the demand for a preventive measure. Its application is crucial for both endemic and epidemic regions, primarily targeting populations in affected areas including children, travelers, and individuals with high exposure risks. The end-use scope extends to government immunization programs, private healthcare providers, and non-governmental organizations engaged in disease prevention efforts.

Key growth factors include technological advancements in vaccine development, increasing governmental initiatives for immunization, and the escalating burden of dengue in affected areas. Opportunities lie in expanding the vaccine's accessibility and affordability, enhancing public awareness, and penetrating emerging markets with high disease prevalence. Strategic partnerships for research and development (R&D) and distribution could offer competitive advantages. However, market growth is hindered by challenges such as the high cost of vaccine development, regulatory constraints, and varying efficacy across different dengue serotypes.

Limitations also include the potential for adverse reactions and public skepticism about vaccine safety and efficacy. Innovations in this sector could focus on improving vaccine efficacy across all serotypes, integrating new technologies for vaccine delivery, and enhancing production scalability. Advanced research in genomics and bioinformatics could provide insights into better targeting of the virus and overcoming resistance. The nature of this market is dynamic, driven by ongoing research, collaborations between biotechnology firms and public health agencies, and global health initiatives. Companies should focus on partnerships, investment in R&D, and expanding market reach to capitalize on potential growth opportunities. Collaboration with governmental bodies for regulatory support and funding could further accelerate market expansion.

Understanding Market Dynamics in the Dengue Vaccine Market

The Dengue Vaccine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
    • Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
    • Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
    • Rising public awareness and education campaigns about the importance of dengue vaccination
  • Market Restraints
    • High R&D and clinical trial costs
  • Market Opportunities
    • Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
    • Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
    • Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
  • Market Challenges
    • Logistical issues in vaccine delivery and vaccine hesitancy

Exploring Porter’s Five Forces for the Dengue Vaccine Market

Porter’s Five Forces framework further strengthens the insights of the Dengue Vaccine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dengue Vaccine Market

External macro-environmental factors deeply influence the performance of the Dengue Vaccine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dengue Vaccine Market

The Dengue Vaccine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dengue Vaccine Market

The Dengue Vaccine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dengue Vaccine Market

The Dengue Vaccine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dengue Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, Bio Farma, Biological E. Limited, CSL Limited, CureVac AG, GeneOne Life Science, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medigen Vaccine Biologics Corp., Merck & Co., Inc., Panacea Biotec, PaxVax, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Vabiotech.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Vaccine Type
    • DNA Vaccines
    • Inactivated Vaccines
    • Live Attenuated Vaccines
    • Recombinant Vaccines
    • Subunit Vaccines
  • End User
    • Clinics
    • Government and Non-Government Organizations
    • Hospitals
    • Research Institutes
  • Age Group
    • Adolescent
    • Adult
    • Pediatric
  • Vaccine Development Stage
    • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
    • Pre-Clinical
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Route of Administration
    • Injection
    • Nasal
    • Oral
  • Technology
    • Conventional Vaccines
      • Split Virus Vaccines
      • Whole Virus Vaccines
    • Next-Generation Vaccines
      • Virus-Like Particles
  • Patient Type
    • Symptomatic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
5.1.1.2. Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
5.1.1.3. Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
5.1.1.4. Rising public awareness and education campaigns about the importance of dengue vaccination
5.1.2. Restraints
5.1.2.1. High R&D and clinical trial costs
5.1.3. Opportunities
5.1.3.1. Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
5.1.3.2. Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
5.1.3.3. Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
5.1.4. Challenges
5.1.4.1. Logistical issues in vaccine delivery and vaccine hesitancy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dengue Vaccine Market, by Vaccine Type
6.1. Introduction
6.2. DNA Vaccines
6.3. Inactivated Vaccines
6.4. Live Attenuated Vaccines
6.5. Recombinant Vaccines
6.6. Subunit Vaccines
7. Dengue Vaccine Market, by End User
7.1. Introduction
7.2. Clinics
7.3. Government and Non-Government Organizations
7.4. Hospitals
7.5. Research Institutes
8. Dengue Vaccine Market, by Age Group
8.1. Introduction
8.2. Adolescent
8.3. Adult
8.4. Pediatric
9. Dengue Vaccine Market, by Vaccine Development Stage
9.1. Introduction
9.2. Clinical Trials
9.3. Phase I
9.4. Phase II
9.5. Phase III
9.6. Pre-Clinical
10. Dengue Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Dengue Vaccine Market, by Route of Administration
11.1. Introduction
11.2. Injection
11.3. Nasal
11.4. Oral
12. Dengue Vaccine Market, by Technology
12.1. Introduction
12.2. Conventional Vaccines
12.2.1. Split Virus Vaccines
12.2.2. Whole Virus Vaccines
12.3. Next-Generation Vaccines
12.3.1. Virus-Like Particles
13. Dengue Vaccine Market, by Patient Type
13.1. Introduction
13.2. Symptomatic
14. Americas Dengue Vaccine Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Dengue Vaccine Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Dengue Vaccine Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2023
17.2. FPNV Positioning Matrix, 2023
17.3. Competitive Scenario Analysis
17.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DENGUE VACCINE MARKET RESEARCH PROCESS
FIGURE 2. DENGUE VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
FIGURE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DENGUE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DENGUE VACCINE MARKET DYNAMICS
TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. CANADA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 80. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 81. CANADA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. CANADA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CANADA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 85. CANADA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 86. CANADA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 130. CHINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. CHINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 133. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. CHINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. CHINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CHINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 137. CHINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 138. CHINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 140. INDIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. INDIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 143. INDIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. INDIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. INDIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. INDIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 147. INDIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 148. INDIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 160. JAPAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. JAPAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 163. JAPAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. JAPAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. JAPAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 167. JAPAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 168. JAPAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 220. THAILAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. THAILAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 223. THAILAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. THAILAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. THAILAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. THAILAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 227. THAILAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 228. THAILAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 250. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. DENMARK DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 254. DENMARK DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. DENMARK DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. DENMARK DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 258. DENMARK DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 259. DENMARK DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 261. EGYPT DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. EGYPT DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 264. EGYPT DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. EGYPT DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. EGYPT DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 268. EGYPT DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 269. EGYPT DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. FINLAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 274. FINLAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. FINLAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. FINLAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. FINLAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 278. FINLAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 279. FINLAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 280. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 281. FRANCE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. FRANCE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 284. FRANCE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. FRANCE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. FRANCE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. FRANCE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 288. FRANCE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 289. FRANCE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 291. GERMANY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. GERMANY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 294. GERMANY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. GERMANY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. GERMANY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. GERMANY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 298. GERMANY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 299. GERMANY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 311. ITALY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. ITALY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 314. ITALY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. ITALY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. ITALY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 317. ITALY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 318. ITALY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 319. ITALY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 340. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 341. NORWAY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. NORWAY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 343. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 344. NORWAY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. NORWAY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 346. NORWAY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 347. NORWAY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
TABLE 348. NORWAY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
TABLE 349. NORWAY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 350. POLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 351. POLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 352.

Companies Mentioned

The leading players in the Dengue Vaccine Market, which are profiled in this report, include:
  • AstraZeneca
  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • CSL Limited
  • CureVac AG
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corp.
  • Merck & Co., Inc.
  • Panacea Biotec
  • PaxVax, Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.02 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Dengue Vaccine Market Report 2024 - Product Image

Dengue Vaccine Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Dengue Vaccine - Global Strategic Business Report - Product Image

Dengue Vaccine - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Dengue Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Dengue Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 104 Pages
  • Global
From
Therapeutic Vaccines Market by Vaccines Type, Disease Indication, Administration, End-User - Global Forecast 2025-2030 - Product Image

Therapeutic Vaccines Market by Vaccines Type, Disease Indication, Administration, End-User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Plotkin's Vaccines. Edition No. 8 - Product Image

Plotkin's Vaccines. Edition No. 8

  • Book

About the Dengue Vaccine Market

The Dengue Vaccine market is a subset of the larger Vaccines market. Dengue is a mosquito-borne virus that can cause severe flu-like symptoms and can be fatal in some cases. Vaccines are the most effective way to prevent dengue infection. The Dengue Vaccine market is composed of a variety of products, including live attenuated vaccines, inactivated vaccines, and recombinant vaccines. These products are used to protect against all four serotypes of the dengue virus. The Dengue Vaccine market is highly competitive, with many companies vying for market share. Companies in the market include Sanofi Pasteur, Merck, GlaxoSmithKline, Takeda, and Bharat Biotech. These companies are actively developing and marketing dengue vaccines to meet the growing demand for protection against the virus. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.